Prescription Patterns of Antihypertensive Medications Among Prolanis Patients at the Outpatient Clinic of Ciracas District Public Health Center, East
DOI:
https://doi.org/10.58511/v3i1.10217Kata Kunci:
Antihypertension, Monotherapy, Combination Therapy, Prescribing Pattern, ProlanisAbstrak
Appropriate hypertension management in Chronic Disease Management Program (Prolanis) patients is crucial to control blood pressure and prevent long-term cardiovascular complications. This study aimed to evaluate the prescribing pattern of antihypertensive drugs in Prolanis patients in outpatient clinics. This descriptive observational study with a cross-sectional design analyzed prescription data from 832 hypertensive patients who met the inclusion criteria. The majority of patients were women (80.60%) with the largest age group being in the range of 41–59 years (61.10%) and age ≥60 years (31.10%). The prescribing pattern was dominated by monotherapy at 60.5% (n = 503), which massively used Calcium Channel Blocker (CCB) in the form of Amlodipine (96.8% of total monotherapy). Two-drug combination therapy was administered to 38.5% of patients (n = 320), with CCB + ACE Inhibitor (Amlodipine + Lisinopril) regimen as the most dominant choice (83.4%). Three-drug combination therapy was very rare (1.1%), but noted a minor polypharmacy anomaly in the form of duplication of Amlodipine preparation therapy. The antihypertensive prescribing pattern in Prolanis patients was largely in line with national and international clinical guidelines through the selection of Amlodipine and the effective combination of Amlodipine-Lisinopril. However, optimization of early initiation of two-drug combination therapy for productive age and supervision of rational prescribing need to be improved to ensure patient safety. Keywords: Amlodipine, Antihypertensive, Monotherapy, Prescribing Pattern, Prolanis, Combination Therapy.
Referensi
[1] Zhou, Bin, et al. "Worldwide trends in hypertension prevalence and progress in treatment and control from 1990 to 2019: a pooled analysis of 1201 population-representative studies with 104 million participants." The lancet. 2021; 398(10304): 957-980.
[2] World Health Organization. Global report on hypertension: the race against a silent killer. Geneva: World Health Organization. 2023.
[3] Febriawati, Henni, et al. Pelaksanaan Program Pengelolaan Penyakit Kronis (Prolanis). Citra Delima Scientific Journal of Citra Internasional Institute. 2022; 6(2): 105-110.
[4] Mancia Giuseppe, Kreutz Reinhold, Brunstrom Mattias, Burnier Michel, Grassi Guido, et al.. "2023 ESH Guidelines for the management of arterial hypertension The Task Force for the management of arterial hypertension of the European Society of Hypertension: Endorsed by the International Society of Hypertension (ISH) and the European Renal Association (ERA). Journal Of Hypertension. 2023; 41(1): 1874, 2023.
[5] Saputri, Eka Oktaviani, Enrico Adhitya Rinaldi, and Tinon Ambarini. "Pengaruh Ketersediaan Obat, Waktu Tunggu Resep, dan Pemberian Informasi Obat Terhadap Loyalitas Pasien Rawat Jalan Di RS Islam Al Mucthar Karawang." Jurnal Manajemen dan Administrasi Rumah Sakit Indonesia (MARSI). 2026; 10(1): 52-67.
[6] World Health Organization. Guideline for the pharmacological treatment of hypertension in adults. Geneva: World Health Organization; 2021.
[7] Mills KT, Stefanescu A, He J. The global epidemiology of hypertension. Nat Rev Nephrol. 2020;16(4):223-237.
[8] Oliveros E, Patel H, Kyung S, Fugar S, Goldberg A, Madan N, et al. Hypertension in older adults: Assessment, management, and challenges. Clin Cardiol. 2020;43(2):99-107.
[9] McEvoy JW, McCarthy CP, Bruno RM, Brouwers S, Canavan MD, Ceconi C, et al. 2024 ESC Guidelines for the management of elevated blood pressure and hypertension. Eur Heart J. 2024;45(38):3912-4018.
[10] Williams B, Mancia G, Spiering W, Agabiti Rosei E, Azizi M, Burnier M, et al. 2018 ESC/ESH Guidelines for the management of arterial hypertension. Eur Heart J. 2018;39(33):3021–3104.
[11] Unger T, Borghi C, Charchar F, Khan NA, Poulter NR, Prabhakaran D, et al. International Society of Hypertension Global Hypertension Practice Guidelines. Hypertension. 2020;75(6):1334–1357.
[12] Indonesian Society of Hypertension (InaSH). Konsensus Penatalaksanaan Hipertensi 2021. Jakarta: InaSH; 2021.
[13] Puspitasari IM, Sinuraya AL, Arisanti N, Alfian SD. Evaluation of antihypertensive medication utilization and blood pressure control in primary care facilities in Indonesia. J Multidiscip Healthc. 2020; 13:1633–41.
[14]Whelton PK, Carey RM, Aronow WS, Casey DE, Collins KJ, Dennison Himmelfarb C, et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults. Hypertension. 2018;71(6): 1269-1324.
[15] Maas AH, Rosano G, Cifkova R, Chieffo A, van Dijken S, Rieska M, et al. Cardiovascular health in women: a statement from the European Society of Cardiology Staff for the European Society of Cardiology. Eur Heart J. 2021;42(12):1161–1169.
[16] Kementerian Kesehatan Republik Indonesia. Formularium Nasional. Jakarta: Ministry of Health of the Republic of Indonesia. 2025.
[17] BPJS Kesehatan. Panduan Pelayanan Program Jaminan Kesehatan Nasional. Jakarta: BPJS Kesehatan. 2024.
[18] Burnier M, Egan BM. Adherence in hypertension. Circ Res. 2019;124(7):1124-1140.
[19] Thomopoulos C, Parati G, Zanchetti A. Effects of blood pressure-lowering treatment on cardiovascular outcomes and cost-effectiveness: overview of meta-analyses. J Hypertens. 2020;38(11):2169-2179.

